II. Mechanism

  1. Extracellular CTLA4 fused to Fc of IgG1
  2. Inhibits CD28 to CD80/CD66 binding
  3. Increases T-Cell Activation threshold and inhibits T-Cell proliferation

III. Dosing

  1. IV infusion: 10 mg/kg to 500, 750 or 1000 mg over 30 minutes
  2. Initial: 0, 2 and 4 months and then every 4 months

IV. Indications

V. Contraindications

  1. Do not use with TNF Antagonist agent, and probably Anankira
  2. Live virus Vaccine within the last 3 months

Images: Related links to external sites (from Bing)

Related Studies